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The adaptation of cancer cells to the constantly 
changing conditions of their microenvironment during 
tumor progression requires dynamic and flexible 
mechanisms. Glioblastoma and other tumors cells require 
a continuous flux of nutrients and oxygen to sustain 
growth and elevated metabolism; yet, there is often 
insufficient supply of blood and energy to nourish this 
growth/metabolism. While the adaptive mechanisms to 
reduced oxygen (hypoxia) have been well defined, the 
adaptations to fluctuations in the major energy nutrient 
– i.e. glucose, are poorly comprehended. It is likely that 
the successful survival of a cancer cell depends on its 
ability to frequently and dynamically adjust for nutrient 
fluctuations.
Reprogrammed glucose metabolism as a result of 
increased glycolysis and glucose uptake is a hallmark of 
numerous solid tumors and it was recently demonstrated 
that enhancing glucose uptake is one of the mechanisms 
of adaptation of glioblastoma cells to limited glucose 
availability [1]. The preferred uptake of glucose by 
cancer cells led us to hypothesize that in addition to 
an intracellular “sensor” pathway that monitors the 
fluctuations of environmental glucose; there must be the 
effector mechanisms that mediate adaptative response. 
It is known that cells exposed to low glucose 
become metabolically stressed. This results in a shortage 
of ATP, increasing the [AMP]/[ATP] ratio that activates the 
5’AMP-activated protein kinase (AMPK) complex. AMPK 
is a highly conserved energy sensor belonging to a class 
of serine/threonine kinases that controls cell metabolism 
during environmental stress. When cellular energy levels 
are decreased (and thus the AMP/ATP ratio is increased), 
AMPK is phosphorylated by LKB1 [2]. Although the role 
of LKB1/AMPK axis in metabolic homeostasis is well 
documented, its function in cancer is much less clear. Our 
group has shown that the non-coding microRNA - miR-
451, is a potent inhibitor of the AMPK signaling pathway 
[3] directly targeting CAB39 - a necessary LKB1 co-
activator. Glucose availability modulated the expression 
of miR-451 in glioblastoma cells. High glucose led to high 
levels of miR-451, shutting-off AMPK function, inhibiting 
cell migration and elevating cell proliferation. Conversely, 
low glucose led to AMPK activation, which diminished 
the levels of miR-451, inhibited cell growth and turned on 
a migratory phenotype [3]. These observations led us to 
postulate the existence of an AMPK/miR-451 reciprocal 
negative feedback loop, mediated by glucose availability. 
However, the molecular effectors facilitating the low 
glucose/active AMPK-mediated drop in miR-451 levels 
were not known.
In our recent study, we showed that indeed the 
miR-451/AMPK loop is transcriptionally regulated [4]. 
Regardless of the tested experimental glucose regimen 
(withdrawal, gradual depletion, or surge replenishment), 
the levels of the primary transcript of miR-451 were 
dynamically and reversibly linked to glucose status. The 
analysis of the region upstream to the miR-451 genomic 
locus revealed multiple putative binding sites for OCT1 - a 
widely expressed transcription factor [5]. We demonstrated 
that the dynamic binding of OCT1 to its predicted binding 
sites located 6–8 kb upstream of the miR-451 locus led 
to the recruitment of RNA polymerase II and initiated 
the transcription of miR-451 gene. OCT1 transcriptional 
activity (i.e. the ability to bind DNA) is inhibited by the 
phosphorylation at Ser 335 [5]. In low glucose conditions, 
active AMPK directly phosphorylates OCT1 at Ser 335, 
preventing its function. This mechanism thus links glucose 
availability to OCT1’s transcriptional function on the miR-
451 promoter. 
Oct1-deficient cells are resistant to glucose 
deprivation due to a reduction of glucose metabolism 
[6] and are characterized by exceptionally low levels of 
miR-451. Conversely, in AMPK-deficient cells, OCT1 
remained largely dephosphorylated in low glucose, 
resulting in the expression of miR-451 [4]. These results 
thus show that the AMPK/OCT1/miR-451/LKB1 loop 
provides a nutrient-dependent regulatory mechanism to 
allow the cell to adapt to changing microenvironmental 
conditions.
Because AMPK can impede cell growth, it was 
historically perceived as a bona fide tumor suppressor. 
However, recently, a number of studies have emerged 
that lead to the opposite conclusion, namely that the 
AMPK complex endows cancer cells with the ability 
to survive “stressors”, including energy and growth 
factor deficiency and genomic damage [7]. It provides a 
potent regulatory mechanism by which cancer cells are 
capable of temporarily halt their growth as they face 
microenvironmental and therapy-inflicted challenges. 
Thus, AMPK can be perceived as a contextual oncogene, 
enabling cancer cells with behavioral and biochemical 
flexibility.
Both, energy-conserving metabolic shift and 
resource-seeking behavioral change require brain tumor 
cell to shut down miR-451, while forced expression 
of miR-451 during stress leads to cytotoxicity [3]. The 
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AMPK-dependent inactivation of the OCT1 transcriptional 
activator of miR-451 helps brain tumor cells to escape 
from metabolically stressful events/locations. MiR-
451 thus provides an example of a molecule that is not 
deregulated in brain tumor cells, but is instead finely 
regulated by promoting or suppressing brain tumor cell 
phenotypes based on microenvironmental contexts.
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